
IMAGES IN CLINICAL MEDICINE

Metastatic Calcification and Long-Term Hemodialysis



Nitesh Rao, M.D. Susan Crail, F.R.A.C.P., Ph.D.

Royal Adelaide Hospital Adelaide, SA, Australia niteshnrao@yahoo.co.uk

by hypertensive nephrosclerosis and was undergoing maintenance hemodialysis. A radiograph of the pelvis and femur revealed extensive calcifications (arrow) in the muscles and subcutaneous tissues of the lower abdominal wall, gluteal regions, and outer thighs, in addition to vascular calcification (arrowhead) and osteopenia. There was no evidence of fracture. The patient was receiving warfarin because of atrial fibrillation. She also had secondary hyperparathyroidism due to renal failure; a month before the administration of cinacalcet was begun, she had a parathyroid hormone level of 73.1 pmol per liter (normal range, 0.8 to 5.5) and a product of the calcium level times the phosphorus level of 5.2 mmol² per square liter (65 mg² per square deciliter; reference range, <4.4 mmol² per square liter [<55 mg² per square deciliter]). Secondary hyperparathyroidism, a high calcium–phosphorus product, and warfarin have been associated with metastatic calcification and calcific uremic arteriolopathy (calciphylaxis), especially in patients undergoing dialysis. Warfarin inhibits γ -carboxylation of matrix Gla protein (a protein that inhibits calcification). The administration of warfarin was stopped, and aggressive management of calcium and phosphorus levels was continued. Although the biochemical variables improved, the patient continues to have pain, which is a notable feature of calcific uremic arteriolopathy. Attempts to manage her pain continue.

DOI: 10.1056/NEJMicm1202544
Copyright © 2013 Massachusetts Medical Society.